Ureteral Stent Discomfort and Its Management
Purpose of Review
Ureteral stent placement is a very common urologic procedure and a necessary component of many minimally invasive surgeries including ureteroscopy. Despite its widespread use, stent placement results in bothersome urinary symptoms and pain in approximately 80% of patients. This review discusses the proposed mechanisms underlying ureteral stent-related symptoms and current approaches to symptom management and the evidence to support them.
Though it has been extensively studied, the exact cause of stent-related symptoms remains unknown but is likely related to irritation of the bladder by the distal curl of the stent and reflux of urine through the stent up to the renal pelvis and transmission of high pressures associated with this. Recent research has focused on trying to modify stents including the creation of drug eluting stents as well as preventing symptoms with intravesical instillation of medications in the operative room at the time of placement. Some of these approaches show promise, but anticholinergic and alpha-blocking medications remain the only treatments for stent-related symptoms with reasonable evidence to support them.
Current evidence suggests that a multimodal approach to stent-related symptoms and pain with alpha-blockers, anticholinergic medications, and anti-inflammatory and narcotic pain medications is likely the most effective. Further research is needed to better investigate many novel techniques for decreasing stent-related symptoms. This continues to be an important area of research given the need for ureteral stents in urology and the high prevalence of patient discomfort related to stent placement.
KeywordsUreteral stent Stent-related pain Stent-related voiding symptoms
Compliance with Ethical Standards
Conflict of Interest
Katherine M. Fischer and Michael Louie each declare no potential conflicts of interest.
Phillip Mucksavage is a section editor for Current Urology Reports.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.• Joshi HB, et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060–4. The ureteral stent symptoms questionnaire (USSQ) described and validated in this paper is the only validated measure to study specifically stent-related symptoms. This measure is used by most groups investigating therapies to improve stent-related symptoms and is therefore important to be familiar with and understand. CrossRefPubMedGoogle Scholar
- 29.Taguchi M, Inoue T, Muguruma K, Murota T, Kinoshita H, Matsuda T. Impact of loop-tail ureteral stents on ureteral stent-related symptoms immediately after ureteroscopic lithotripsy: comparison with pigtail ureteral stents. Investigative and clinical urology. 2017;58(6):440–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, Brock GB, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004;18(8):723–30.CrossRefPubMedGoogle Scholar
- 43.•• Zhou L, Cai X, Li H, Wang KJ. Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol. 2015;29:650. This meta-analysis found that both anticholinergics and alpha-blockers decrease stent discomfort with the combination of both types of medications being superior to monotherapy.–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Zhang YM, Chu P, Wang WJ. PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: a meta-analysis. Medicine. 2017;96(7)Google Scholar
- 46.Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71(5):792–5.CrossRefPubMedGoogle Scholar